gmp
gmp

Find Clinical Drug Pipeline Developments & Deals by AMRI

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual BoothA partner for the pharma and biotech industries to improve patient outcomes & quality of life

            Contact the Supplier

            Lead Product(s): ChAdOx1 nCoV-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: AstraZeneca PLC

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 03, 2020

            Details:

            AMRI has been chosen to contribute to the supply of the vaccine candidate through sterile fill/finish of AZD1222 at AMRI’s drug product manufacturing facility in Albuquerque, New Mexico.

            Virtual BoothA partner for the pharma and biotech industries to improve patient outcomes & quality of life

            Contact the Supplier

            Lead Product(s): Psilocybine

            Therapeutic Area: Psychiatry/Psychology Product Name: TRP-8802

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Tryp Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership August 13, 2020

            Details:

            AMRI will provide research, development and cGMP manufacturing of a proprietary psilocybin active pharmaceutical ingredient to support the clinical development of TRP-8802, TRP-8803 and TRP-8804 programs.

            Virtual BoothA partner for the pharma and biotech industries to improve patient outcomes & quality of life

            Contact the Supplier

            Lead Product(s): Merimepodib,Remdesivir

            Therapeutic Area: Infections and Infectious Diseases Product Name: VX-497

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: BioSig Technologies

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership July 08, 2020

            Details:

            The companies together are undertaking research to investigate the potential of merimepodib to fight SARS-CoV-2, the virus that causes COVID-19, either as a stand-alone treatment or in combination with other antiviral agents or immune modulators.